Builds portable systems that preserve and assess donor hearts, lungs and livers, and provides organ-procurement, perfusion-management and transport services to transplant centers.
10-K for FY2025, filed Feb 24, 2026We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease…View ↗
We designed the OCS to be a platform that allows us to leverage core technologies across products for multiple organs. To date, we have…View ↗
We developed the NOP to provide additional capabilities to transplant centers for the complicated organ procurement process that often…View ↗
Transplant centers buy single-use sets for transplant procedures, consoles, and NOP procurement, perfusion-management and logistics services. Revenue from each product or service is earned when it is delivered.
10-K for FY2025, filed Feb 24, 2026The Company generates net product revenue primarily from sales of its single-use, organ-specific disposable sets used on its organ-specific…View ↗
Customer orders may include the loan of an OCS Console as well as OCS disposable sets used in each transplant procedure. When the Company…View ↗
Revenue is recognized when control is transferred to the customer in an amount that reflects the consideration the Company expects to be…View ↗
$605.5M
10-K for FY2025, filed Feb 24, 2026
$605.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Cost of net product revenue
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
62%
FY2022: 85%
|
Cost of net product revenue, FY2025
$372.4M Sources
|
Sold outright |
|
Cost of service revenue
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
39%
FY2022: 15%
|
Cost of service revenue, FY2025
$233.1M Sources
|
Sold outright |
Transplant centers are end customers worldwide: U.S. centers can outsource procurement and logistics through the NOP or buy OCS products directly and train their own teams. A small portion of sales goes through distributors in Europe and Asia-Pacific.
10-K for FY2025, filed Feb 24, 2026We commercialize our products through two channels: our NOP and a direct acquisition model. Our NOP enables transplant centers to outsource…View ↗
Our direct acquisition model is provided to transplant centers to train their own teams for organ procurement and OCS perfusion management…View ↗
The Company markets and sells its products to end customers globally. A small portion of the Company’s revenue is generated by sales to a…View ↗
Yes. It kept 31 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Sep 10, 2026
TransMedics is reiterating its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25%…View ↗
8-K, filed Aug 4, 2026
TransMedics is raising the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million. This guidance…View ↗
Growing. Revenue grew 20.0x in 4 years, from $30.3M in FY2021 to $605.5M in FY2025, about 111% a year.
Expanded NOP logistics
The NOP has grown from an outsourced organ-retrieval and OCS-management service into an offering that also coordinates aviation and ground transport, including dedicated aircraft.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 24, 2026We developed the NOP to provide additional capabilities to transplant centers for the complicated organ procurement process that often…View ↗
We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease…View ↗
We developed the NOP to provide additional capabilities to transplant centers for the complicated organ procurement process that often…View ↗
In August 2023, we acquired Summit Aviation, Inc. and Northside Property Group, LLC, or together Summit. Summit was a charter flight…View ↗
Added a kidney product in development
The older report described development for additional organs generally; the latest report identifies a kidney product in development that will use the newer multi-organ platform.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 24, 2026We developed the OCS, the first and only FDA approved portable, multi-organ, warm perfusion platform, to leverage proprietary core…View ↗
We developed the OCS, the first and only FDA approved portable, multi-organ, warm perfusion platform, to leverage proprietary core…View ↗
Added European logistics activity
The older report described European distribution and commercial operations; the latest report also describes building logistics support for the NOP in European regions.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 24, 2026Our corporate headquarters, manufacturing and clinical training facilities are located in Andover, Massachusetts. We also have a…View ↗
Expand internationally in key European countries. We believe international expansion could represent an additional growth driver for us in…View ↗
Loading...